# Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

> **NCT04401995** · PHASE2 · COMPLETED · sponsor: **Diwakar Davar** · enrollment: 9 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vidutolimod (CMP-001)
- **BIOLOGICAL:** Nivolumab
- **OTHER:** [18F]F-AraG PET/CT

## Key facts

- **NCT ID:** NCT04401995
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-02
- **Primary completion:** 2024-08-16
- **Final completion:** 2024-08-16
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401995, "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04401995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*